Multinational observational cohort study of covid-19-associated pulmonary aspergillosis1

Nico A. F. Janssen; R. my Nyga; Lore Vanderbeke; Cato Jacobs; Mehmet Ergün; Jochem B. Buil; Karin van Dijk; Josje Altenburg; Catherine S. C. Bouman; Hans I. van der Spoel; Bart J. A. Rijnders; Albert Dunbar; Jeroen A. Schouten; Katrien Lagrou; Marc Bourgeois; Marijke Reynders; Niels van Regenmortel; Lynn Rutsaert; Piet Lormans; Simon Feys; Yves Debavaye; Fabienne Tamion; Damien Costa; Julien Maizel; Hervé Dupont; Taieb Chouaki; Saad Nseir; Boualem Sendid; Roger J. M. Brüggemann; Frank L. van de Veerdonk; Joost Wauters; Paul E. Verweij

doi:https://doi.org/10.3201/eid2711.211174

Multinational observational cohort study of covid-19-associated pulmonary aspergillosis1

Nico A. F. Janssen, R. my Nyga, Lore Vanderbeke, Cato Jacobs, Mehmet Ergün, Jochem B. Buil, Karin van Dijk, Josje Altenburg, Catherine S. C. Bouman, Hans I. van der Spoel, Bart J. A. Rijnders, Albert Dunbar, Jeroen A. Schouten, Katrien Lagrou, Marc Bourgeois, Marijke Reynders, Niels van Regenmortel, Lynn Rutsaert, Piet Lormans, Simon FeysYves Debavaye, Fabienne Tamion, Damien Costa, Julien Maizel, Hervé Dupont, Taieb Chouaki, Saad Nseir, Boualem Sendid, Roger J. M. Brüggemann, Frank L. van de Veerdonk, Joost Wauters, Paul E. Verweij

Research output: Contribution to journal › Article › Academic › peer-review

82 Citations (Scopus)

Abstract

We performed an observational study to investigate intensive care unit incidence, risk factors, and outcomes of coronavirus disease-associated pulmonary aspergillosis (CAPA). We found 10%-15% CAPA incidence among 823 patients in 2 cohorts. Several factors were independently associated with CAPA in 1 cohort and mortality rates were 43%-52%.

Original language	English
Pages (from-to)	2892-2898
Number of pages	7
Journal	Emerging infectious diseases
Volume	27
Issue number	11
DOIs	https://doi.org/10.3201/eid2711.211174
Publication status	Published - 2021

Access to Document

https://doi.org/10.3201/eid2711.211174

Cite this

Janssen, N. A. F., Nyga, R. M., Vanderbeke, L., Jacobs, C., Ergün, M., Buil, J. B., van Dijk, K., Altenburg, J., Bouman, C. S. C., van der Spoel, H. I., Rijnders, B. J. A., Dunbar, A., Schouten, J. A., Lagrou, K., Bourgeois, M., Reynders, M., van Regenmortel, N., Rutsaert, L., Lormans, P., ... Verweij, P. E. (2021). Multinational observational cohort study of covid-19-associated pulmonary aspergillosis1. Emerging infectious diseases, 27(11), 2892-2898. https://doi.org/10.3201/eid2711.211174

@article{b1953816fbd14caf8f40d390f5afa0a7,

title = "Multinational observational cohort study of covid-19-associated pulmonary aspergillosis1",

abstract = "We performed an observational study to investigate intensive care unit incidence, risk factors, and outcomes of coronavirus disease-associated pulmonary aspergillosis (CAPA). We found 10%-15% CAPA incidence among 823 patients in 2 cohorts. Several factors were independently associated with CAPA in 1 cohort and mortality rates were 43%-52%.",

author = "Janssen, {Nico A. F.} and Nyga, {R. my} and Lore Vanderbeke and Cato Jacobs and Mehmet Erg{\"u}n and Buil, {Jochem B.} and {van Dijk}, Karin and Josje Altenburg and Bouman, {Catherine S. C.} and {van der Spoel}, {Hans I.} and Rijnders, {Bart J. A.} and Albert Dunbar and Schouten, {Jeroen A.} and Katrien Lagrou and Marc Bourgeois and Marijke Reynders and {van Regenmortel}, Niels and Lynn Rutsaert and Piet Lormans and Simon Feys and Yves Debavaye and Fabienne Tamion and Damien Costa and Julien Maizel and Herv{\'e} Dupont and Taieb Chouaki and Saad Nseir and Boualem Sendid and Br{\"u}ggemann, {Roger J. M.} and {van de Veerdonk}, {Frank L.} and Joost Wauters and Verweij, {Paul E.}",

note = "Funding Information: during the study period and nonfinancial support from Gilead Sciences and Pfizer for work outside the submitted study. J.B.B. reports grants from F2G, Gilead Sciences, and Thermo Fisher Scientific for work outside the submitted study. B.J.A.R. reports grants from Gilead Sciences for work outside the submitted study. K.L. reports nonfinancial support from Pfizer and personal fees from SMB Laboratoires, Gilead Sciences, FUJIFILM Wako, Thermo Fisher Scientific, and MSD for work outside the submitted study. S.N. reports personal fees from MSD, Pfizer, Gilead, bioM{\'e}rieux, and Bio-Rad for work outside the submitted study. K.L. received consultancy fees from MSD, SMB Laboratoires Brussels, and Gilead; nonfinancial support from Pfizer and MSD, speaker fees from Gilead Sciences, FUJIFILM WAKO, and Pfizer; and a grant from Thermo Fisher Scientific, for work outside the submitted study. R.J.M.B. has served as a consultant to Astellas Pharma, Inc., F2G, Amplyx, Gilead Sciences, Merck Sharp & Dohme Corp., Mundipharma, and Pfizer, Inc., and has received unrestricted and research grants from Astellas Pharma, Inc., Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc., for work outside the submitted study; all contracts were through Radboudumc, and all payments were invoiced by Radboudumc. J.W. reports grants from Gilead during the study period, grants and nonfinancial support from MSD, and grants from Pfizer for work outside the submitted study. P.E.V. reports grants from Mundipharma, F2G, Pfizer, Thermofisher, Gilead Sciences, and Cidara and nonfinancial support from IMMY for work outside the submitted study. Funding Information: L.V. reports grants from the Research Foundation Flanders Publisher Copyright: {\textcopyright} 2021 Centers for Disease Control and Prevention (CDC). All rights reserved.",

year = "2021",

doi = "https://doi.org/10.3201/eid2711.211174",

language = "English",

volume = "27",

pages = "2892--2898",

journal = "Emerging infectious diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "11",

}

Janssen, NAF, Nyga, RM, Vanderbeke, L, Jacobs, C, Ergün, M, Buil, JB, van Dijk, K , Altenburg, J, Bouman, CSC, van der Spoel, HI, Rijnders, BJA, Dunbar, A, Schouten, JA, Lagrou, K, Bourgeois, M, Reynders, M, van Regenmortel, N, Rutsaert, L, Lormans, P, Feys, S, Debavaye, Y, Tamion, F, Costa, D, Maizel, J, Dupont, H, Chouaki, T, Nseir, S, Sendid, B, Brüggemann, RJM, van de Veerdonk, FL, Wauters, J & Verweij, PE 2021, 'Multinational observational cohort study of covid-19-associated pulmonary aspergillosis1', Emerging infectious diseases, vol. 27, no. 11, pp. 2892-2898. https://doi.org/10.3201/eid2711.211174

TY - JOUR

T1 - Multinational observational cohort study of covid-19-associated pulmonary aspergillosis1

AU - Janssen, Nico A. F.

AU - Nyga, R. my

AU - Vanderbeke, Lore

AU - Jacobs, Cato

AU - Ergün, Mehmet

AU - Buil, Jochem B.

AU - van Dijk, Karin

AU - Altenburg, Josje

AU - Bouman, Catherine S. C.

AU - van der Spoel, Hans I.

AU - Rijnders, Bart J. A.

AU - Dunbar, Albert

AU - Schouten, Jeroen A.

AU - Lagrou, Katrien

AU - Bourgeois, Marc

AU - Reynders, Marijke

AU - van Regenmortel, Niels

AU - Rutsaert, Lynn

AU - Lormans, Piet

AU - Feys, Simon

AU - Debavaye, Yves

AU - Tamion, Fabienne

AU - Costa, Damien

AU - Maizel, Julien

AU - Dupont, Hervé

AU - Chouaki, Taieb

AU - Nseir, Saad

AU - Sendid, Boualem

AU - Brüggemann, Roger J. M.

AU - van de Veerdonk, Frank L.

AU - Wauters, Joost

AU - Verweij, Paul E.

N1 - Funding Information: during the study period and nonfinancial support from Gilead Sciences and Pfizer for work outside the submitted study. J.B.B. reports grants from F2G, Gilead Sciences, and Thermo Fisher Scientific for work outside the submitted study. B.J.A.R. reports grants from Gilead Sciences for work outside the submitted study. K.L. reports nonfinancial support from Pfizer and personal fees from SMB Laboratoires, Gilead Sciences, FUJIFILM Wako, Thermo Fisher Scientific, and MSD for work outside the submitted study. S.N. reports personal fees from MSD, Pfizer, Gilead, bioMérieux, and Bio-Rad for work outside the submitted study. K.L. received consultancy fees from MSD, SMB Laboratoires Brussels, and Gilead; nonfinancial support from Pfizer and MSD, speaker fees from Gilead Sciences, FUJIFILM WAKO, and Pfizer; and a grant from Thermo Fisher Scientific, for work outside the submitted study. R.J.M.B. has served as a consultant to Astellas Pharma, Inc., F2G, Amplyx, Gilead Sciences, Merck Sharp & Dohme Corp., Mundipharma, and Pfizer, Inc., and has received unrestricted and research grants from Astellas Pharma, Inc., Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc., for work outside the submitted study; all contracts were through Radboudumc, and all payments were invoiced by Radboudumc. J.W. reports grants from Gilead during the study period, grants and nonfinancial support from MSD, and grants from Pfizer for work outside the submitted study. P.E.V. reports grants from Mundipharma, F2G, Pfizer, Thermofisher, Gilead Sciences, and Cidara and nonfinancial support from IMMY for work outside the submitted study. Funding Information: L.V. reports grants from the Research Foundation Flanders Publisher Copyright: © 2021 Centers for Disease Control and Prevention (CDC). All rights reserved.

PY - 2021

Y1 - 2021

N2 - We performed an observational study to investigate intensive care unit incidence, risk factors, and outcomes of coronavirus disease-associated pulmonary aspergillosis (CAPA). We found 10%-15% CAPA incidence among 823 patients in 2 cohorts. Several factors were independently associated with CAPA in 1 cohort and mortality rates were 43%-52%.

AB - We performed an observational study to investigate intensive care unit incidence, risk factors, and outcomes of coronavirus disease-associated pulmonary aspergillosis (CAPA). We found 10%-15% CAPA incidence among 823 patients in 2 cohorts. Several factors were independently associated with CAPA in 1 cohort and mortality rates were 43%-52%.

UR - http://www.scopus.com/inward/record.url?scp=85118128803&partnerID=8YFLogxK

U2 - https://doi.org/10.3201/eid2711.211174

DO - https://doi.org/10.3201/eid2711.211174

M3 - Article

C2 - 34519638

SN - 1080-6040

VL - 27

SP - 2892

EP - 2898

JO - Emerging infectious diseases

JF - Emerging infectious diseases

IS - 11

ER -

Multinational observational cohort study of covid-19-associated pulmonary aspergillosis1

Abstract

Access to Document

Other files and links

Cite this